Sandoz announces agreement with Gan & Lee Pharmaceutical to commercialise biosimilar insulins.
Fuji Pharma announces acquisition of 4.2% stake in Alvotech for roughly $50 million.
Fuji Pharma and Alvotech announce exclusive partnership agreement for the commercialisation of Alvotech’s biosimilars in Japan. Fuji Pharma will be responsible for the registration and commercialisation of products, while Alvotech will be responsible for development and supply.
Biogen and Samsung Bioepis close asset transfer to increase Biogen’s share in Samsung Bioepis to 49.9%. This deal originates from the initial creation of Samsung Bioepis and the partnership between Biogen and Samsung BioLogics, in which Biogen was granted an option to increase its share in the company, expiring in mid 2018.
Munidpharma acquires Cinfa Biotech, gaining immediate access to pegfilgrastim biosimilar and a platform to potentially develop more biosimilars in the future.
Merck secures 5 year, $117.5M deal with US Department of Veterans Affairs to supply rituximab biosimilar developed by Samsung.
US-Mexico-Canada Agreement includes 10 year exclusivity period for biologic drugs, raising concerns that competition will be hindered to the disadvantage of consumers and health services in those regions. Currently the exclusivity period stands at 8 years in Canada and 5 years in Mexico.
iBio and CC-Pharming enter agreement to develop biosimilar rituxumab for the Chinese market.
Catalent announced a collaboration for the development and manufacture of Valerius’ biosimilar products. Catalent will provide cell line development and support cGMP manufacturing activities from Phase 1 through to commercial stages from the USA.
Although details have not been announced by the companies, it appears that Korea’s Alteogen, and Malaysia’s Inno Bio Ventures are setting up a biosimilars JV in Malaysia, with an ASEAN focus. Read more
Californian HQ’d BioSciences Corp & Shanghai based Mab-Venture announce a deal under which Mab-Venture will develop and manufacture biosimilars and BioSciences Corp will commercialise (through partners) those products in India, SAARC, MENA, Turkey, LatAm and Russia. The deal covers “multiple” products which have not been named. Read more
Sandoz and Biocon announce a collaboration to develop and commercialise multiple biosimilar medicines. The companies will share responsibility for development, manufacturing and regulatory approvals. Sandoz is responsible for leading commercialisation in the US & EU, while Biocon will lead commercialisation efforts in the rest of the world.
Product specific reports based on extracts from our BioBlast® database
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.